111
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer

, , , , , , , , , & show all
Pages 169-180 | Published online: 23 Oct 2018

Figures & data

Table 1 Characteristics of 121 patients who underwent IMRT

Figure 1 Chronological changes of IPSS (A), QOL question index (B), and OABSS (C).

Notes: *P<0.05, **P<0.01, ***P<0.001 (compared to baseline using Dunnett test). HP, at the HP in IMRT; 0, immediately after IMRT; 1, 1 month after IMRT; 3, 3 months after IMRT; 6, 6 months after IMRT; 12, 12 months after IMRT; 24, 24 months after IMRT.
Abbreviations: BL, baseline; HP, halfway point; IMRT, intensity-modulated radiotherapy; IPSS, International Prostate Symptom Score; OABSS, Overactive Bladder Symptom Score; QOL, quality of life.
Figure 1 Chronological changes of IPSS (A), QOL question index (B), and OABSS (C).

Figure 2 Chronological changes of urinary (A), bowel (B), sexual (C), and hormone domain (D) summary score in EPIC.

Notes: *P<0.05, **P<0.01, ***P<0.001 (compared to baseline using Dunnett test). HP, at the HP in IMRT; 0, immediately after IMRT; 1, 1 month after IMRT; 3, 3 months after IMRT; 6, 6 months after IMRT; 12, 12 months after IMRT; 24, 24 months after IMRT.
Abbreviations: BL, baseline; EPIC, Expanded Prostate Cancer Index Composite; HP, halfway point; IMRT, intensity-modulated radiotherapy.
Figure 2 Chronological changes of urinary (A), bowel (B), sexual (C), and hormone domain (D) summary score in EPIC.

Figure 3 Chronological changes of the sexual summary score without ADT (A), with ADT as neoadjuvant therapy (B), and with ADT as neoadjuvant plus adjuvant therapy (C).

Notes: HP, at the HP in IMRT; 0, immediately after IMRT; 1, 1 month after IMRT; 3, 3 months after IMRT; 6, 6 months after IMRT; 12, 12 months after IMRT; 24, 24 months after IMRT.
Abbreviations: ADT, androgen deprivation therapy; BL, baseline; HP, halfway point; IMRT, intensity-modulated radiotherapy.
Figure 3 Chronological changes of the sexual summary score without ADT (A), with ADT as neoadjuvant therapy (B), and with ADT as neoadjuvant plus adjuvant therapy (C).

Figure 4 Chronological changes of the hormone summary score without ADT (A), with ADT as neoadjuvant therapy (B), and with ADT as neoadjuvant plus adjuvant therapy (C).

Notes: HP, at the HP in IMRT; 0, immediately after IMRT; 1, 1 month after IMRT, 3, 3 months after IMRT; 6, 6 months after IMRT; 12, 12 months after IMRT; 24, 24 months after IMRT.
Abbreviations: ADT, androgen deprivation therapy; BL, baseline; HP, halfway point; IMRT, intensity-modulated radiotherapy.
Figure 4 Chronological changes of the hormone summary score without ADT (A), with ADT as neoadjuvant therapy (B), and with ADT as neoadjuvant plus adjuvant therapy (C).

Figure 5 Chronological changes of physical functioning (A), role physical (B), bodily pain (C), general health (D), vitality (E), social functioning (F), role emotional (G), and mental health (H) in SF-8.

Notes: *P<0.05, **P<0.01, ***P<0.001 (compared to baseline using Dunnett test). HP, at the HP in IMRT; 0, immediately after IMRT; 1, 1 month after IMRT; 3, 3 months after IMRT; 6, 6 months after IMRT; 12, 12 months after IMRT; 24, 24 months after IMRT.
Abbreviations: BL, baseline; HP, halfway point; IMRT, intensity-modulated radiotherapy.
Figure 5 Chronological changes of physical functioning (A), role physical (B), bodily pain (C), general health (D), vitality (E), social functioning (F), role emotional (G), and mental health (H) in SF-8.

Table S1 Time course changes in IPSS, QOL question score, and OABSS after IMRT

Table S2 Time course changes in EPIC questionnaire score after IMRT

Table S3 Time course changes in SF-8 after IMRT